• 1
    Duncan J. Medical factors affecting quality of life in patients with epilepsy. In: Round Table Series 23. London : Royal Society of Medicine; 1990: 807.
  • 2
    Engel J. The epilepsies. In: WyngaardenJB, SmithLH, BennettJC, eds. Cecil textbook of medicine. 19th ed. Philadelphia : WB Saunders, 1992: 220213.
  • 3
    Roberts E. Failure of GABAergic inhibition: a key to local and global seizures. Adv Neurol 1986; 44: 31941.
  • 4
    Meldrum BS. GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br J Clin Pharmacol 1989; 28 (suppl 1): 311.
  • 5
    Schechter PJ, Hanke NFJ, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of y-vinyl GABA in patients with epilepsy. Neurology 1984; 34: 1826.
  • 6
    Grove J, Schechter PJ, Tell G, et al. Increased gamma-amino-butyric acid (GABA), homocarnosine and β-alanine in cerebrospinal fluid of fluid of patients treated with y-vinyl GABA (4-amino-hex-5-enoic acid). Life Sci 1981; 28: 24319.
  • 7
    Reynolds EH. Gamma-vinyl GABA (vigabatrin): clinical experience in adult and adolescent patients with intractable epilepsy. Epilepsia 1992; 33 (suppl 5): S304.
  • 8
    Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889926.
  • 9
    Rall TW, Schleifer LS. Drugs effective in the therapy of the epilepsies. In: GilmanAG, RallTW, NiesAS, TaylorP, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York : Pergamon Press, 1990: 43662.
  • 10
    Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990; 18: 22538.
  • 11
    Peyster RG, Sussman NM, Hershey BL, et al. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia 1995; 36: 93100.
  • 12
    Jackson GD, Williams SR, Weller RO, et al. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res 1994; 18: 5766.
  • 13
    Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314: 1801.
  • 14
    Harding GFA. Severe persistent visual field constriction associated with vigabatrin: benefit/risk must be calculated for individual patients. BMJ 1998; 316: 2323.
  • 15
    French JA, Mosier M, Walker S, Sommerville K, Sussman N. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 1996; 46: 5461.
  • 16
    Mumford JP, Dam M. Meta-analysis of European placebo-controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989; 27: 1017.
  • 17
    Sivenius MRJ, Ylinen A, Murros K, Matilainen R, Riekkinen P. Double-blind dose reduction study of vigabatrin in complex partial epilepsy. Epilepsia 1987; 28: 68892.
  • 18
    Tartara A, Manni R, Galimberti CA, et al. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurol Scand 1992; 86: 24751.
  • 19
    Sivenius J, Ylinen A, Murros K, Mumford JP, Riekkinen PJ. Vigabatrin in drug-resistant partial epilepsy: a 5-year follow-up study. Neurology 1991; 41: 5625.
  • 20
    Sander J, Trevisol-Bittencourt PC, Hart YM, Shorvon SD. Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. J Neurol Neurosurg Psychiatry 1990; 53: 100810.
  • 21
    Ben-Menachem E, Persson L, Mumford J. Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy. Epilepsy Res 1990; 5: 2406.
  • 22
    McGuire AM, Duncan JS, Trimble MR. Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia 1992; 33: 12834.
  • 23
    Dijkstra JB, McGuire AM, Trimble MR. Effect of vigabatrin on cognitive function and mood. Hum Psychopharmacol 1992; 7: 31923.